High-risk lineages among extended-spectrum β-lactamase-producing Escherichia coli from extraintestinal infections in Maputo Central Hospital, Mozambique.


Journal

International journal of antimicrobial agents
ISSN: 1872-7913
Titre abrégé: Int J Antimicrob Agents
Pays: Netherlands
ID NLM: 9111860

Informations de publication

Date de publication:
Oct 2022
Historique:
received: 12 01 2022
revised: 29 07 2022
accepted: 31 07 2022
pubmed: 8 8 2022
medline: 28 9 2022
entrez: 7 8 2022
Statut: ppublish

Résumé

Extended-spectrum β-lactamase (ESBL)-producing extraintestinal pathogenic Escherichia coli (ExPEC), particularly high-risk lineages, are responsible for severe infections and increased mortality and hospital costs worldwide, with a major burden in low-income countries. Here we determined the antimicrobial susceptibility and performed whole-genome sequencing of E. coli isolates from extraintestinal infections of patients during 2017-2018 at Maputo Central Hospital (Mozambique). Multidrug resistance was displayed by 71% of isolates (17/24). All isolates resistant to cefotaxime and ceftazidime were positive for ESBL genes (16/24; 67%) and were co-resistant to amoxicillin/clavulanate (14/16; 88%), piperacillin/tazobactam (8/16; 50%), gentamicin (12/16; 75%), trimethoprim/sulfamethoxazole (15/16; 94%) and ciprofloxacin (11/16; 69%). Several major high-risk ExPEC lineages were identified, such as H30Rx-ST131, fimH41-ST131, H24Rx-ST410, ST617, ST361 and ST69 harbouring bla

Identifiants

pubmed: 35934230
pii: S0924-8579(22)00165-0
doi: 10.1016/j.ijantimicag.2022.106649
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Carbapenems 0
Escherichia coli Proteins 0
Gentamicins 0
Clavulanic Acid 23521W1S24
Ciprofloxacin 5E8K9I0O4U
Amoxicillin 804826J2HU
Trimethoprim, Sulfamethoxazole Drug Combination 8064-90-2
Ceftazidime 9M416Z9QNR
Iron E1UOL152H7
beta-Lactamases EC 3.5.2.6
Cefotaxime N2GI8B1GK7
Tazobactam SE10G96M8W
Piperacillin X00B0D5O0E

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

106649

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None declared.

Auteurs

Antonella Santona (A)

Department of Biomedical Sciences, University of Sassari, Sassari, Italy. Electronic address: asantona@uniss.it.

José João Sumbana (JJ)

Department of Biomedical Sciences, University of Sassari, Sassari, Italy; Department of Biological Sciences, Eduardo Mondlane University, Maputo, Mozambique; Microbiology, Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique.

Maura Fiamma (M)

Department of Biomedical Sciences, University of Sassari, Sassari, Italy.

Massimo Deligios (M)

Department of Biomedical Sciences, University of Sassari, Sassari, Italy.

Elisa Taviani (E)

Department of Biomedical Sciences, University of Sassari, Sassari, Italy.

Samuel Elija Simbine (SE)

Microbiology, Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique.

Tomas Zimba (T)

Maputo Central Hospital, Maputo, Mozambique.

Jahit Sacarlal (J)

Microbiology, Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique.

Salvatore Rubino (S)

Department of Biomedical Sciences, University of Sassari, Sassari, Italy.

Bianca Paglietti (B)

Department of Biomedical Sciences, University of Sassari, Sassari, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH